Inhaled nitric oxide to treat intermediate risk pulmonary embolism: A multicenter randomized controlled trial

AbstractIntroductionthe current worldwide outbreak of Coronavirus disease 2019 (COVID-19) due to a novel coronavirus (SARS-CoV-2) is seriously threatening the public health. The number of infected patients is continuously increasing and the need for Intensive Care Unit admission ranges from 5 to 26%. The mortality is reported to be around 3.4% with higher values for the elderly and in patients with comorbidities. Moreover, this condition is challenging the healthcare system where the outbreak reached its highest value. To date there is still no available treatment for SARS-CoV-2. Clinical and preclinical evidence suggests that nitric oxide (NO) has a beneficial effect on the coronavirus-mediated acute respiratory syndrome, and this can be related to its viricidal effect. The time from the symptoms’ onset to the development of severe respiratory distress is relatively long. We hypothesize that high concentrations of inhaled NO administered during early phases of COVID-19 infection can prevent the progression of the disease.Methods and analysisThis is a multicenter randomized controlled trial. Spontaneous breathing patients admitted to the hospital for symptomatic COVID-19 infection will be eligible to enter the study. Patients in the treatment group will receive inhaled NO at high doses (140-180 parts per million) for 30 minutes, 2 sessions every day for 14 days in addition to the hospital care. Patient in the control group will receive only hospital care. The primary outcome is the percentage of patients requiring endotracheal intubation due to the progression of the disease in the first 28 days from enrollment in the study. Secondary outcomes include mortality at 28 days, proportion of negative test for SARS-CoV-2 at 7 days and time to clinical recovery.Ethics and disseminationThe trial protocol has been approved at the Investigation Review Boards of Xijing Hospital (Xi’an, China) and The Partners Human Research Committee of Massachusetts General Hospital (Boston, USA) is pending. Recruitment is expected to start in March 2020. Results of this study will be published in scientific journals, presented at scientific meetings, and on related website or media in fighting this widespread contagious disease.Trial registrationClinicaltrials.gov. NCT submitted

Download Full-text

Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism

Circulation ◽

10.1161/circulationaha.113.005544 ◽

2014 ◽

Vol 129 (4) ◽

pp. 479-486 ◽

Cited By ~ 400

Author(s):

Nils Kucher ◽

Peter Boekstegers ◽

Oliver J. Müller ◽

Christian Kupatt ◽

Jan Beyer-Westendorf ◽

...

Keyword(s):

Pulmonary Embolism ◽

Randomized Controlled Trial ◽

Controlled Trial ◽

Intermediate Risk ◽

Randomized Controlled ◽

Catheter Directed Thrombolysis ◽

Ultrasound Assisted

Download Full-text

Inhaled nitric oxide as an adjunct to neonatal resuscitation in premature infants: a pilot, double blind, randomized controlled trial

Pediatric Research ◽

10.1038/s41390-019-0643-x ◽

2019 ◽

Vol 87 (3) ◽

pp. 523-528 ◽

Cited By ~ 1

Author(s):

Krishnamurthy Sekar ◽

Edgardo Szyld ◽

Michael McCoy ◽

Anne Wlodaver ◽

Douglas Dannaway ◽

...

Keyword(s):

Nitric Oxide ◽

Randomized Controlled Trial ◽

Premature Infants ◽

Controlled Trial ◽

Neonatal Resuscitation ◽

Inhaled Nitric Oxide ◽

Double Blind ◽

Randomized Controlled

Download Full-text

Protocol of a randomized controlled trial testing inhaled Nitric Oxide in mechanically ventilated patients with severe acute respiratory syndrome in COVID-19 (SARS-CoV-2)

10.1101/2020.03.09.20033530 ◽

2020 ◽

Cited By ~ 4

Author(s):

Chong Lei ◽

Binxiao Su ◽

Hailong Dong ◽

Andrea Bellavia ◽

Raffaele Di Fenza ◽

...

Keyword(s):

Nitric Oxide ◽

Randomized Controlled Trial ◽

Severe Acute Respiratory Syndrome ◽

Antiviral Activity ◽

Controlled Trial ◽

Inhaled Nitric Oxide ◽

Rt Pcr ◽

Severe Hypoxemia ◽

Randomized Controlled ◽

Refractory Hypoxemia

AbstractIntroductionSevere acute respiratory syndrome (SARS-CoV-2) due to novel Coronavirus (2019-nCoV) related infection (COVID-19) is characterized by severe ventilation perfusion mismatch leading to refractory hypoxemia. To date, there is no specific treatment available for 2019-nCoV. Nitric oxide is a selective pulmonary vasodilator gas used as a rescue therapy in refractory hypoxemia due to acute respiratory distress syndrome (ARDS). In has also shown in-vitro and clinical evidence that inhaled nitric oxide gas (iNO) has antiviral activity against other strains of coronavirus. The primary aim of this study is to determine whether inhaled NO improves oxygenation in patients with hypoxic SARS-CoV2. This is a multicenter randomized controlled trial with 1:1 individual allocation. Patients will be blinded to the treatment.Methods and analysisIntubated patients admitted to the intensive care unit with confirmed SARS-CoV-2 infection and severe hypoxemia will be randomized to receive inhalation of NO (treatment group) or not (control group). Treatment will be stopped when patients are free from hypoxemia for more than 24 hours. The primary outcome evaluates levels of oxygenation between the two groups at 48 hours. Secondary outcomes include rate of survival rate at 28 and 90 days in the two groups, time to resolution of severe hypoxemia, time to achieve negativity of SARS-CoV-2 RT-PCR tests.Ethics and disseminationThe study protocol has been approved by the Investigational Review Board of Xijing Hospital (Xi’an, China) and pending the Partners Human Research Committee (Boston, USA). Recruitment will start after approval of both IRBs and local IRBs at other enrolling centers. Results of this study will be published in scientific journals, presented at scientific meetings, reported through flyers and posters, and published on related website or media in combating against this widespread contagious diseases.Trial registrationClinicaltrials.gov. NCT submittedStrengths and limitations of this study— Supplementation with nitric oxide (NO) might improve oxygenation and survival of SARS-CoV-2 patients.— The antiviral activity of NO inhalation will be explored by measuring the time difference between the two groups to reach SARS-CoV-2 RT- PCR negativity.— The spread of the disease worldwide determines the geographic areas of study and the recruitment rate of patients.

Download Full-text